AxoGen (AXGN) Azione Prezzo
AxoGen Prezzo
Il fatturato è cresciuto a un tasso composto del 48,3% annuo negli ultimi 19 anni, raggiungendo 225,21 Mio. USD. Il margine netto di AxoGen si attesta al -7,0%, in aumento rispetto al -21,2% di alcuni anni fa. AxoGen offre attualmente un rendimento da dividendo di circa il 2,77%. Gli analisti fissano un target di prezzo mediano di 51,50 USD, ovvero il 42,9% sopra il prezzo attuale. Su 16 analisti, 15 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
AxoGen Prezzo delle azioni
AxoGen Azione e analisi azionaria
Domande frequenti sull'azione AxoGen
AxoGen Inc is a leading medical technology company focused on the development and commercialization of innovative solutions for peripheral nerve injuries. Their business model revolves around providing advanced surgical solutions to patients suffering from nerve damage. AxoGen offers a comprehensive portfolio of products and services that support nerve repair and regeneration, enabling patients to regain function and improve their quality of life. Through their cutting-edge technologies, AxoGen aims to revolutionize the field of peripheral nerve repair, bringing hope and relief to individuals with nerve injuries.
AxoGen Inc is primarily active in the healthcare industry.
The main competitors of AxoGen Inc in the market include Integra LifeSciences Holdings Corporation, Baxter International Inc., Stryker Corporation, and Medtronic plc.
AxoGen Inc. is a biotechnology company specializing in the development and commercialization of innovative surgical solutions for peripheral nerve injuries. Founded in 2002, AxoGen is headquartered in Alachua, Florida, and operates globally. The company is dedicated to advancing the science and understanding of nerve injury and regeneration through its proprietary Avance® Nerve Graft and AxoGuard® Nerve Protector products. With an experienced management team, AxoGen continues to drive innovation in nerve repair and restoration, providing hope and improved outcomes for patients suffering from nerve damage. AxoGen Inc. has established itself as a leader in the field, offering groundbreaking solutions to healthcare providers and patients worldwide.
AxoGen Inc has achieved several significant milestones throughout its history. The company has successfully developed and commercialized innovative nerve repair technology, making it a leader in the field. AxoGen has achieved FDA clearance and European CE mark approval for its products. It has also expanded its market presence by establishing distribution agreements with leading healthcare providers globally. AxoGen has consistently demonstrated strong financial performance, with increased revenues and record-breaking sales. The company's commitment to research and development has led to numerous patents and the introduction of groundbreaking surgical solutions. Overall, AxoGen Inc has made remarkable progress in transforming the field of nerve repair and continues to pave the way for future advancements.
AxoGen Inc is primarily present in the United States.
AxoGen Inc represents the values of innovation, collaboration, and patient-centricity. As a leading company in the field of nerve repair and regeneration, AxoGen is dedicated to developing and providing innovative solutions for patients with peripheral nerve injuries. Their corporate philosophy revolves around improving patient outcomes and enhancing the quality of life by delivering safe and effective treatments. By prioritizing collaboration with healthcare professionals and researchers, AxoGen ensures that their products are developed with the latest scientific advancements. With an unwavering commitment to patient well-being, AxoGen continues to make significant contributions to the field of nerve repair.
Gli analisti fissano attualmente un prezzo obiettivo medio di 50,17 USD per l’azione AxoGen (mediana: 51,50 USD), pari a +39,2 % rispetto all’ultimo prezzo. Il consenso si basa su 16 giudizi di analisti.
16 analisti valutano attualmente l’azione AxoGen: 15 raccomandano l’acquisto, 1 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per AxoGen ricavi pari a 279,56 Mio. USD e un utile per azione di 0,44 USD.
Convertita al tasso di cambio attuale, l’azione AxoGen quota 32,18 EUR (36,04 USD).
L’azione AxoGen (AXGN) è quotata su 4 borse, tra cui: NASDAQ (AXGN), London (0HKD.L), Frankfurt (LT3.F).
AxoGen Inc is a medical device company specializing in the development, manufacturing, and marketing of nerve repair products. The company, founded in 2002 in Florida, USA, aims to help improve patients' quality of life and alleviate pain and impairments caused by damages to peripheral nerves. They offer a range of products tailored to the specific needs of patients with nerve injuries, including the AxoGuard® Nerve Protector, biologics, regenerative medicine, neurostimulation, and the AxoTouch Test. The AxoGuard® Nerve Protector is designed to prevent damage to peripheral nerves and consists of breathable, implantable sleeves that provide protection. It is typically used to protect or repair nerves after surgery or due to injuries. Biologics, another branch of AxoGen Inc, involves the use of biological materials to accelerate the healing process of injured nerves, such as stem cells, Botulinum toxin injection, and antibodies to promote repair. Regenerative medicine products utilize regenerative forces to accelerate healing and promote the formation of new tissue, with Avance® Nerve Graft being the flagship product made from frozen human nerves processed mechanically and enzymatically to obtain a highly pure and biocompatible product. Neurostimulation focuses on the use of electronic devices to stimulate the nervous system, helping to alleviate pain and expedite healing. AxoStim® electrostimulation systems are among the products in this field. The AxoTouch Test is a diagnostic tool used to diagnose nerve damage, measuring pressure and touch sensitivity in the patient's body. It consists of a handheld instrument, a touch sensitivity measurement device, and specialized software packages for data analysis. AxoGen Inc's business model revolves around providing products for nerve damage regeneration, offering a comprehensive range of products tailored to patients' specific needs. The company is dedicated to developing innovative technologies and products to enhance the lives of individuals suffering from nerve damage and associated pain and impairments.
Il attesa fatturato di AxoGen ammonta a 279,56 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di AxoGen ammonta a 20,57 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di AxoGen è attualmente 82,20. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione AxoGen.
Il rapporto prezzo/fatturato (P/S) di AxoGen è attualmente 6,05. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione AxoGen.
Il Quality Score AlleAktien per AxoGen è 4/10.
L'ISIN di AxoGen è US05463X1063. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di AxoGen è A1JMHK. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di AxoGen è AXGN. Con questo simbolo di borsa vengono negoziate le azioni AxoGen in borsa.
Azione AxoGen
Gruppo di pari di AxoGen
AxoGen Ticker
AxoGen FIGI
Altre metriche e analisi di AxoGen in Deep Dive.
La nostra analisi azionaria dell'azione AxoGen include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di AxoGen. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: